Brooks Laboratories share news and announcements
NSE: BROOKSBSE: 533543Pharmaceuticals & BiotechnologySmall Cap
Last close ₹57.86down ₹3.23 (5.29%)BSE ₹58.02
Share price at the NSE close on 23 Oct 2026. Previous close ₹61.09.
52-week range of traded prices to 23 Oct 2026
₹36.30Low, 30 Mar 2026₹123.54High, 23 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹170 Cr2,450th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 12.9
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 1.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 12.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 3.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 99,20064.6% delivered
Brooks Laboratories share news and announcements
454 announcements, routine notices left out, newest first. Page 10 of 10.
Nov 2011
2 Nov · Board meeting
To discuss and approve the un audited provisional results for quarter ending September 30, 2011.
Oct 2011
14 Oct · Board meeting
For the following business : (1) To discuss and declare the Bonus for employees; (2) To discuss and decide for availing the buyers credit facility; (3) To take note of the general progress of the Company.
Sep 2011
19 Sep · Board meeting
Board of Directors of the Company at its meeting held on September 19, 2011, inter alia, discussed and decided the following matters: (1) Board appoints Dr. D. S. Maity as Chief Executive Officer of the Company w.e.f. September 19, 2011, (2) Board appoints Mr. Ketan Shah as Chief Financial Officer of the Company w.e.f. September 19, 2011.(3) Board approved the draft and adopts the code of conducts of the Company.16 Sep · Board meeting
For the following business : (1) To appoint Chief Executive Officer; (2) To appoint Chief Financial Officer; (3) To discuss and adopt the Code of Conducts.